Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. develops and commercializes medicines for rare diseases, with recurring updates centered on product sales, clinical readouts, regulatory interactions and employee equity grants. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis.
News about MIRM also covers clinical-stage programs including volixibat, an IBAT inhibitor for primary sclerosing cholangitis and primary biliary cholangitis; brelovitug, a monoclonal antibody designed to bind hepatitis B surface antigen for chronic hepatitis delta virus; and MRM-3379, a PDE4D inhibitor for Fragile X syndrome. Company updates report financial results, pipeline licensing activity and inducement awards under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (Nasdaq:MIRM) granted equity inducement awards to 8 new employees on June 10, 2026 under its 2020 Inducement Plan. Awards include non-qualified stock options for 10,100 shares at an exercise price of $94.00 and 13,350 RSUs.
Stock options vest over four years, with 25% after one year and the remainder monthly over 36 months. RSUs vest over three years in equal annual installments, all subject to continued service.
Incyte (Nasdaq: INCY) and Mirum Pharmaceuticals will present pivotal Phase 2 PROGRESS study results for investigational ALK2 inhibitor zilurgisertib in fibrodysplasia ossificans progressiva (FOP) at ENDO 2026 in Chicago, June 13-16, 2026.
The Cohort 1, placebo-controlled data supported the New Drug Application, which has an FDA Priority Review PDUFA date of September 26, 2026.
Mirum Pharmaceuticals (Nasdaq:MIRM) reported new data for three rare liver disease programs presented at EASL 2026.
Phase 2b VISTAS volixibat data in PSC showed clinically meaningful pruritus and serum bile acid reductions, Phase 2b AZURE-1 brelovitug data showed virologic and ALT responses in HDV, and LIVMARLI improved event-free survival in PFIC versus a real-world cohort. Mirum plans a 2026 NDA for volixibat and targets Phase 3 HDV topline data in 2H 2026.
Mirum Pharmaceuticals (Nasdaq:MIRM) will present new rare liver disease data at the EASL International Liver Congress 2026 in Barcelona from May 27-30, 2026.
Highlights include late-breaking Phase 2b results for volixibat in PSC, brelovitug in HDV, and clinical and real-world data for LIVMARLI (maralixibat) in PFIC and intrahepatic cholestasis of pregnancy.
Mirum Pharmaceuticals (Nasdaq:MIRM) granted equity inducement awards to 12 new employees under its 2020 Inducement Plan on May 11, 2026. Awards include non-qualified stock options for 22,950 shares at an exercise price of $106.17 and 31,300 RSUs, issued under Nasdaq Listing Rule 5635(c)(4).
Options vest over four years; RSUs vest over three years, subject to continued service.
Mirum Pharmaceuticals (Nasdaq:MIRM) priced $600.0 million of 0.00% convertible senior notes due 2032 in a Rule 144A private placement, with a $90.0 million option for additional notes.
Net proceeds are estimated at $583.8–$671.6 million, partly used to refinance 4.00% 2029 notes and for general corporate purposes.
Mirum Pharmaceuticals (Nasdaq:MIRM) plans a private offering of $600 million convertible senior notes due 2032 to qualified institutional buyers under Rule 144A, with an option for an additional $90 million. Proceeds will partly fund cash consideration in exchanges of its 4.00% convertible notes due 2029 and support general corporate purposes, including possible acquisitions.
Mirum Pharmaceuticals (Nasdaq:MIRM) will participate in two upcoming investor conferences in May 2026. Management will join fireside chats at the H.C. Wainwright 4th Annual BioConnect Investor Conference and the 2026 RBC Capital Markets Global Healthcare Conference.
Live and archived webcasts will be available in the Investors section of Mirum’s website.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported Q1 2026 net product sales of $159.9 million and raised 2026 net product sales guidance to $660–$680 million. LIVMARLI sales were $113.8 million (+55% YoY); Bile Acid Medicines sales were $46.1 million (+20% YoY). Clinical updates: volixibat VISTAS and brelovitug AZURE-1 Phase 2b met primary endpoints. Mirum licensed zilurgisertib for FOP; the FDA accepted the NDA and granted Priority Review with a PDUFA date of Sept 26, 2026. Q1 operating expenses included a $726.3 million non-recurring IPR&D charge; cash, cash equivalents, and investments were $420.6 million as of March 31, 2026.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that the VISTAS Phase 2b study of volixibat in primary sclerosing cholangitis met its primary endpoint. In the primary cohort (n=111) volixibat showed an LS mean itch change of -2.72 versus -1.08 for placebo; placebo-adjusted difference -1.64 (p<0.0001). Secondary signals included ≥2-point responder rate 55.6% vs 26.3% (difference 29.3%, p=0.0019) and sBA reduction. Safety showed more GI events, liver lab elevations, and higher discontinuations with volixibat. A pre-NDA meeting with FDA is scheduled for summer 2026 and an NDA filing is planned in H2 2026; full results will be presented May 30 at EASL.